8-K: BioCardia's CardiALLO Heart Failure Trial Receives Positive DSMB Review, Study to Proceed as Designed

BioCardia announces that the independent Data Safety Monitoring Board (DSMB) recommended the CardiALLO Heart Failure Phase 1/2 clinical trial continue as designed after reviewing 30-day safety data from the 20 million cell dosing cohort.

Summary

• BioCardia, Inc. announced a positive review from the independent Data Safety Monitoring Board (DSMB) for its CardiALLO Heart Failure Phase 1/2 clinical trial on April 15, 2025.
• The DSMB recommended the trial continue as designed after reviewing 30-day safety data from the 20 million cell dosing cohort.
• No treatment emergent major adverse cardiac events or clinical evidence of immune reactions to the allogeneic cells implanted were observed.
• The company plans to enroll 39 participants in the United States.
• The CardiALLO Heart Failure Trial is a Phase I/II study with an open label Phase I nine-patient dose escalation cohort, followed by a thirty-patient randomized double-blinded placebo procedure-controlled cohort.
• Phase I involves treating three patients at escalating doses of 20 million, 100 million, and 200 million cells using the Helix delivery system.
• BioCardia's therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.

Sentiment

Score: 7

Explanation: The document presents a positive update on the CardiALLO trial, with the DSMB recommending the study continue as designed. This suggests progress and potential for future success, but it's still early-stage clinical trial data.

Positives

• The DSMB's recommendation is an important step forward in advancing the allogeneic off-the-shelf mesenchymal stromal/stem cell therapy.
• The positive results could be helpful with ongoing discussions around nondilutive funding and partnering opportunities for BioCardia's MSC platform.
• Success in this trial can enable future pivotal trial design and funding in the USA.
• The trial could lead to conditional time-limited approval with reimbursement in Japan.
• The trial could advance CardiALLO MSC therapy for pediatric and adult congenital heart disease.

Risks

• The press release contains forward-looking statements that are subject to risks and uncertainties.
• Actual results may differ materially from the forward-looking statements.
• Additional factors that could materially affect actual results can be found in BioCardia's Form 10-K filed with the Securities and Exchange Commission on March 26, 2025, under the caption titled Risk Factors.

Future Outlook

The company anticipates that success in the CardiALLO HF trial can enable future pivotal trial design and funding in the USA, conditional time limited approval with reimbursement in Japan, as well as the advancement of CardiALLO MSC therapy for the likely orphan indications of pediatric and adult congenital heart disease.

Management Comments

• 'We are pleased with the DSMBs recommendation, an important step forward in advancing this allogeneic off the shelf mesenchymal stromal/stem cell therapy,' said Peter Altman, BioCardia Chief Executive Officer.
• Altman also stated that today's result has the potential to be helpful with ongoing discussions around nondilutive funding and partnering opportunities for their MSC platform.

Industry Context

The announcement highlights the growing interest in cell-based therapies for cardiovascular diseases. BioCardia is positioning itself as a leader in this space with its CardiALLO and CardiAMP platforms.

Comparison to Industry Standards

• The press release references the TRIDENT trial, which demonstrated that higher MSC cell dosages reduced myocardial scar and increased left ventricular ejection fraction.
• It also mentions peer results indicating that patients with active inflammation have sustained reduction in cardiovascular major morbidity.
• CardiALLO HF at high dosage is anticipated to have at least twice the effective dosage of these previous studies and will be the first trial to target patients with active inflammation.

Stakeholder Impact

• Shareholders may react positively to the news of the DSMB recommendation.
• The results could potentially benefit patients with heart failure if the therapy proves to be safe and effective.
• Positive trial outcomes could lead to increased partnering opportunities and funding for BioCardia.

Next Steps

• The company plans to progress the trial to enrollment of 39 participants in the United States.
• The company will continue discussions around nondilutive funding and partnering opportunities for its MSC platform.

Key Dates

Keywords

CardiALLO, Heart Failure, Clinical Trial, DSMB, BioCardia, Cell Therapy, MSC, Allogeneic